Go or go go? J&J’s cell therapy heads to the FDA

Johnson & Johnson's ciltacabtagene autoleucel could soon become the second approved cell therapy for multiple myeloma, with its Pdufa date falling towards the end of next month. The BCMA-targeted Car-T therapy is gunning to take on Bristol Myers Squibb/Bluebird's Abecma, and boasts better efficacy.

Elsewhere, Biomarin is taking its achondroplasia project back to the regulators after submitting durability data, while a panel will decide whether molnupiravir, Merck & Co/Ridgeback’s oral Covid-19 antiviral, has safety in hand.